In this section, it was demonstrated that cross-modal effects principally occur in the high-quality domain.
The airborne measurements, although spatially uniform and dense, represent very near-surface determinations (e.g. typically less than 0.6 m) and are influenced by a variety of near-surface effects principally those relating to soils and water.
behaviour is described in terms of two regimes: up to ∼ 66 MGy the observed effects principally result from changes in the amorphous regions, whereas at higher doses crystal destruction appears to become increasingly important such that by 260 MGy only a small residual melting peak is observed.
The clinical development of a class of PDE4 inhibitor anti-inflammatory agents has been hindered by their side effects, principally nausea and emesis [ 10].
Vascular endothelial growth factor is considered the most potent angiogenic growth factor, and mediates its effects principally via two receptor tyrosine kinases expressed on endothelial cells, Flt-1 (VEGFR1) and KDR/Flk-1 (VEGFR2).
PGD2 exerts its effects principally by binding and activating two plasma membrane receptors, the D prostanoid receptor (DP) 1 [ 15] and chemoattractant-receptor-like molecule expressed on Th2 cells (CRTH2), also known as DP2 [ 16].
As VEGF contributes to cardiomyocyte function and growth on the one hand and to the integrity and expansion of the coronary and systemic circulation on the other one [ 8, 10, 11, 45, 67– 70], it is not surprising that VEGF antagonism may lead to cardiovascular side effects, principally hypertension, thromboembolism, LV dysfunction, and HF [ 71– 71].
As the action of this mimicking peptide on MOP receptor could only be indirect, that is by decreasing the CDK5-mediated phosphorylation of DOP receptors, our results strongly suggest that the effects principally occur in spinal and DRG neurons co-expressing DOP and MOP receptors, where they may interact to regulate each other's functions.
More recently, razoxane as an orally administered single anti-angiogenic agent was demonstrated in patients with inoperable renal cell cancer to be well tolerated and resulted in acceptable response rates with very low toxicity and minimal side effects, principally nausea and vomiting (Braybrooke et al, 2000).
